1215767-84-2

Usage

Uses

Used in Pharmaceutical Industry:
5-bromo-7-chloroquinoline is used as a building block for the synthesis of various bioactive molecules and pharmaceutical drugs, contributing to the development of new therapeutic agents due to its unique chemical structure and properties.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 5-bromo-7-chloroquinoline is utilized as a precursor for the development of new therapeutic agents, leveraging its chemical reactivity and structural features to create novel compounds with potential medicinal applications.
Used as a Fluorescent Probe:
5-bromo-7-chloroquinoline is employed as a fluorescent probe for studying cellular processes, providing insights into biological mechanisms and interactions within the cellular environment due to its fluorescent properties.
Used in Organic Synthesis:
As a reagent in organic synthesis, 5-bromo-7-chloroquinoline is used to facilitate chemical reactions, enabling the creation of a variety of organic compounds for research and industrial applications.

Upstream product

• 1215767-85-3 5-bromo-7-chloro-8-aminoquinoline 
• 96558-78-0 3-bromo-5-chlorophenylamine 
• 56-81-5 glycerol 
• 578-66-5 8-amino quinoline 
• 53472-18-7 5-bromo-8-aminoquinoline 
• 33757-48-1 N-quinolin-8-yl-benzamide 

Relevant academic research and scientific papers

New compound used as rearranged during transfection kinase inhibitor

The present invention relates to a compound, a pharmaceutical composition containing the compound, a preparation method of the compounds, and application of the same as a rearranged during transfection (RET) kinase inhibitor. The compound is a compound shown as formula (I), or a pharmaceutically acceptable salt, a prodrug, a solvent compound, a polymorph, an isomer and a stable isotope derivativethereof. The present invention also relates to the application of the compounds to treatment or prevention of RET kinase mediated related diseases like tumors and a method of using the compounds for the treatment of the diseases.

Structure-activity relationships, biological evaluation and structural studies of novel pyrrolonaphthoxazepines as antitumor agents

Microtubule-targeting agents (MTAs) are a class of clinically successful anti-cancer drugs. The emergence of multidrug resistance to MTAs imposes the need for developing new MTAs endowed with diverse mechanistic properties. Benzoxazepines were recently identified as a novel class of MTAs. These anticancer agents were thoroughly characterized for their antitumor activity, although, their exact mechanism of action remained elusive. Combining chemical, biochemical, cellular, bioinformatics and structural efforts we developed improved pyrrolonaphthoxazepines antitumor agents and their mode of action at the molecular level was elucidated. Compound 6j, one of the most potent analogues, was confirmed by X-ray as a colchicine-site MTA. A comprehensive structural investigation was performed for a complete elucidation of the structure-activity relationships. Selected pyrrolonaphthoxazepines were evaluated for their effects on cell cycle, apoptosis and differentiation in a variety of cancer cells, including multidrug resistant cell lines. Our results define compound 6j as a potentially useful optimized hit for the development of effective compounds for treating drug-resistant tumors.

NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS

The present invention relates novel 6-6 bicyclic aromatic ring substituted nucleoside analogues of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.

ANTAGONISTS OF PROSTAGLANDIN EP3 RECEPTOR

Provided herein are antagonists la or lb of prostaglandin EP3 receptor, processes to make said antagonists, and methods comprising administering said antagonists to a mammal in need thereof. (Formula I)

GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE

Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.